Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food effect study of AZD1775 in advanced solid tumors
NL-OMON46295Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of adavosertib in Nonhematologic neoplasms (2 arms), sponsored by AstraZeneca. Primary endpoints: Maximum plasma concentration (Cmax) of AZD1775, Area under the plasma concentration-time curve from zero to infinity (AUC) of AZD1775 and 1 more. Started Sep 2017; status: active, not recruiting.
02
Drugs
adavosertib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON46295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46295.